“Efficacy and Safety of Tislelizumab Plus Lenvatinib As First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma ”. Medical Forum Monthly, vol. 35, no. 6, June 2024, http://medicalforummonthly.com/index.php/mfm/article/view/4698.